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As part of the mammalian innate immune response, Toll-like receptors 3 and 4
can signal via the adaptor protein TRIF/TICAM-1 to elicit the production of
type-I interferons and cytokines. Recent studies have suggested an auto-
inhibitory role for the N-terminal domain (NTD) of TRIF. This domain has no
significant sequence similarity to proteins of known structure. In this paper, the
crystallization and X-ray diffraction analysis of TRIF-NTD and its seleno-
methionine-labelled mutant TRIF-NTDA66M/L113M are reported. Thin plate-like
crystals of native TRIF-NTD obtained using polyethylene glycol 3350 as
precipitant diffracted X-rays to 1.9 A˚ resolution. To facilitate phase determina-
tion, two additional methionines were incorporated into the protein at positions
chosen based on the occurrence of methionines in TRIF homologues in different
species. Crystals of the selenomethionine-labelled protein were obtained under
conditions similar to the wild-type protein; these crystals diffracted X-rays to
2.5 A˚ resolution. The TRIF-NTD and TRIF-NTDA66M/L113M crystals have the
symmetry of space groups P212121 and P1, and most likely contain two and four
molecules in the asymmetric unit, respectively. These results provide a sound
foundation for the future structure determination of this novel domain.
1. Introduction
Toll-like receptors (TLRs) are pattern-recognition receptors that
play key roles in the mammalian innate immune response. The
extracellular domain of TLRs binds pathogen-associated molecular
patterns (PAMPs), as well as host-derived factors that are indicative
of danger (Gay & Gangloff, 2007). This enables oligomerization of
TLRs, thus facilitating interactions between the cytoplasmic Toll/
interleukin-1 receptor (TIR) domain of the TLRs with specific TIR-
domain-containing adaptor proteins (O’Neill & Bowie, 2007). The
selective recruitment of one or more specific adaptors to the TLR
activates specific downstream signalling cascades, which trigger a
broad range of inflammatory and antimicrobial responses (Akira et
al., 2006).
Five TIR-domain-containing proteins are usually classified as TLR
adaptors in mammals: MyD88 (myeloid differentiation primary
response gene 88), MAL (MyD88 adaptor-like protein), TRIF [TIR-
domain-containing adaptor inducing interferon (IFN)-]/TICAM-1
(TIR-domain-containing adaptor molecule 1), TRAM (TRIF-related
adaptor molecule) and SARM (sterile  and armadillo motif-
containing protein) (Ve et al., 2012). TRIF acts as the sole signalling
adaptor for TLR3 and can also associate with TLR4 via TRAM,
which leads to the production of type-I IFN and cytokines through
the activation of transcription factors including IRF3 (IFN regulatory
factor 3), NF-B (nuclear factor-B) and AP-1 (activator protein-1)
(Oshiumi, Matsumoto et al., 2003; Yamamoto et al., 2003; Oshiumi,
Sasai et al., 2003; Fitzgerald et al., 2003). Human TRIF consists of 712
amino acids and comprises several domains. The N-terminal region of
TRIF contains a TRAF6 (tumour necrosis factor receptor-associated
factor 6)-binding motif and interacts with TBK1 (Tank-binding
kinase 1), leading to the activation of IRF3 (Sato et al., 2003). The
TIR domain is essential for binding to the TIR domain of TLR3 as
well as to the adaptor TRAM (Oshiumi, Sasai et al., 2003; Fitzgerald
et al., 2003). The C-terminal region contains a receptor-interacting
protein (RIP) homotypic interaction motif (RHIM), which recruits
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RIP1 and RIP3, triggering cell death and NF-B activation (Kaiser &
Offermann, 2005).
Recently, it has been reported that the N-terminal region of TRIF
comprising residues 1–176 corresponds to a protease-resistant
structured domain (Tatematsu et al., 2010). A deletion mutant of
TRIF lacking this region (comprising residues 181–712) showed
higher NF-B-dependent IFN- promoter activation compared with
wild-type TRIF, and an interaction between the N-terminal region
and the TIR domain was demonstrated by immunoprecipitation and
protein fragment complementation analysis. The authors thus
proposed that the N-terminal region folds onto the TIR domain of
TRIF, preventing self-association until the protein is activated.
Knowledge of the structure of the N-terminal region of TRIF will
be of great interest, as it will shed light on the regulation of TRIF and
its interaction with the TIR domain. It also promises to reveal a novel
structure, as it contains no significant sequence similarity to any
proteins of known structure. To this end, we have successfully
expressed, purified and crystallized TRIF-NTD (N-terminal domain
corresponding to residues 1–153 of TRIF) and its mutant containing
two additional Met residues.
2. Materials and methods
2.1. Cloning, protein expression and purification
Fragments encoding residues 1–145, 1–150, 1–153 (TRIF-NTD), 1–
160, 1–177, 5–150, 5–153, 10–150 and 10–153 were amplified by PCR
from full-length human cDNA and cloned into the pMCSG7
expression vector by ligation-independent cloning (LIC; Stols et al.,
2002; for the primers used, see Table 1). The constructs contained an
N-terminal hexahistidine (His) tag followed by a TEV (tobacco etch
virus) protease cleavage site. The integrity of the constructs was
confirmed by sequencing. Subsequently, point mutations were
introduced to incorporate additional methionines into the TRIF-
NTD protein for selenomethionine labelling, yielding the TRIF-
NTDA66M/L113M protein. The mutations were incorporated by
conventional PCR in two steps (introducing one mutation first,
verifying the integrity of the first mutant construct by sequencing and
then introducing the second mutation; for the primers used, see
Table 1).
The proteins were expressed in Escherichia coli BL21 (DE3) cells
using auto-induction media (Studier, 2005). The cells were grown by
continuous shaking at 230 rev min1 in a temperature-controlled bio-
shaker at 310 K in the presence of ampicillin (100 mg l1). The
temperature of the culture was lowered to 293 K when the OD600 nm
reached approximately 0.6–0.8. Subsequently, the cultures were
grown for approximately 16 h before harvesting the cells by centri-
fugation at 5000g at 277 K and storing them at 193 K.
For selenomethionine (SeMet) labelling of TRIF-NTDA66M/L113M,
the construct was expressed in E. coli B834 (DE3) (methionine-
auxotroph) cells (Novagen) using M9 medium supplemented with
0.2 mM SeMet. The cultures were grown at 310 K until the OD600 nm
reached approximately 0.6; at this stage, the temperature of the
cultures was lowered to 293 K and IPTG (isopropyl -d-1-thio-
galactopyranoside) was added to the growing medium to a final
concentration of 1 mM to induce protein expression. The cells were
grown approximately 16 h after induction and harvested by centri-
fugation.
For protein purification, the harvested cells were resuspended in
pre-chilled lysis buffer (50 mM Tris base pH 8.0, 500 mM NaCl,
20 mM imidazole, 1 mM DTT) at a rate of 5 ml buffer per gram of
bacterial cells and lysed using a digital sonifier (Branson). The cell
debris and insoluble material were removed by centrifugation at
15 000g and 277 K. The resulting supernatant was collected and
loaded onto a 5 ml HisTrap FF column (GE Healthcare) which was
pre-equilibrated with lysis buffer. To remove unbound proteins and
contaminants, the column was washed with 20 column volumes of
washing buffer (consisting of 50 mM Tris base pH 8.0, 500 mM NaCl,
30 mM imidazole, 1 mM DTT). A linear gradient of 30–500 mM
imidazole was performed over 20 column volumes to elute the
protein and fractions containing TRIF-NTD (as judged by SDS–
PAGE) were collected. The collected sample was concentrated to
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Table 1
Primers used to generate expression constructs.
Primers used for different TRIF constructs (50 to 30 ; labelled corresponding to the
relevant N- or C-terminal residue in TRIF)
Forward: 1 TACTTCCAATCCAATGCCATGGCCTGCACAGGCCCAT-
CACTTCCTAG
Forward: 5 TACTTCCAATCCAATGCCGGCCCATCACTTCC-
TAGCGCCTTCGAC
Forward: 10 TACTTCCAATCCAATGCCAGCGCCTTCGACATTCTAGG
TGCAGCAGG
Reverse: 145 TTATCCACTTCCAATGTTACCCACACCGGTTTCGGGCCT-
CATCC
Reverse: 150 TTATCCACTTCCAATGTTACCCAGCAATGTCCCACCCA-
CACCGG
Reverse: 153 TTATCCACTTCCAATGTTACCCTGGATCCCCAGCAATG
TCCCACC
Reverse: 160 TTATCCACTTCCAATGTTAGGACTGGAGCGTCCG-
GATGCTCCC
Reverse: 177 TTATCCACTTCCAATGTTAGCTCCTGGTCCCAGAGGG-
CAAAGCC
Primers used for mutagenesis (50 to 30 ; labelled corresponding to the mutation)
Forward: A66M AGAGGCATTGAAGATGGATGCGGTGG
Reverse: A66M CCACCGCATCCATCTTCAATGCCTCT
Forward: L113M CCCCGCCTCGATGCGGGACG
Reverse: L113M CGTCCCGCATCGAGGCGGGG
Table 2
Crystallographic data-collection and processing statistics.
Values in parentheses are for the outer shell.
Protein TRIF-NTD Se-Met-labelled
TRIF-NTDA66M/L113M
Diffraction source MX2, Australian
Synchrotron
MX2, Australian
Synchrotron
Wavelength (A˚) 0.9539 0.9793
Temperature (K) 100 100
Detector ADSC Quantum 315r CCD ADSC Quantum 315r CCD
Crystal-to-detector
distance (mm)
300.000 399.993
Rotation range per image () 0.5 1.0
Total rotation range () 360 1440
Exposure time per image (s) 0.5 1.0
Space group P212121 P1
Unit-cell parameters (A˚, ) a = 48.02, b = 77.18,
c = 85.15,
 =  =  = 90
a = 47.32, b = 49.48,
c = 70.32,  = 88.55,
 = 77.63,  = 72.26
Mosaicity () 0.34 0.20
Resolution range (A˚) 77.18–1.90 (2.01–1.90) 68.62–2.48 (2.63–2.48)
Total No. of reflections 207239 225375
No. of unique reflections 25058 19519
Completeness (%) 99.1 (93.8) 94.8 (68.9)
Anomalous completeness 98.0 (86.7) 93.2 (60.0)
Multiplicity 8.3 11.6
Anomalous multiplicity 4.4 5.8
hI/(I)i 6.1 (1.5) 17.1 (4.5)
Rmeas† 0.206 (1.128) 0.147 (0.614)
Rp.i.m.‡ 0.070 (0.454) 0.043 (0.188)
Overall B factor from
Wilson plot (A˚2)
22.5 21.4
† Rmeas ¼
P
hklfNðhklÞ=½NðhklÞ  1g1=2
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ.
‡ Rp:i:m: ¼
P
hklf1=½NðhklÞ  1g1=2
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ.
2 ml using a 10 000 Da molecular-weight cutoff Amicon (Millipore)
and then diluted in TEV cleavage buffer (50 mM Tris pH 8.0, 250 mM
NaCl, 1 mM DTT, 0.5 mM EDTA) to a volume of 20 ml. To remove
the N-terminal His tag, 800 mg (at a concentration of 8 mg ml1) TEV
protease was added to 20 ml sample and the tag was removed by
overnight digestion. For purification, the digested protein sample was
loaded back onto the HisTrap FF column and purified using the same
IMAC (immobilized metal-affinity chromatography) strategy as
described above. For further purification, the pooled sample was run
over the size-exclusion column (Superdex 75 HiLoad 26/60, GE
Healthcare) using size-exclusion buffer (20 mM HEPES pH 7.5,
150 mM NaCl, 2 mM DTT). Fractions from the peak were analysed
by SDS–PAGE and the purest fractions were pooled together and
concentrated. Native protein was concentrated to 56 mg ml1,
whereas the SeMet-labelled protein was concentrated to 20 mg ml1
in size-exclusion buffer. The concentrated proteins were flash-frozen
in liquid nitrogen in 50 ml aliquots and stored at 193 K. The
concentration of proteins was determined based on the absorbance at
280 nm (NanoDrop ND-1000) using an extinction coefficient of
20 970M1 cm1. Multi-angle laser light scattering (MALLS)
experiments were carried out using a Dawn Heleos II 18-angle light-
scattering detector coupled to an Optilab rEX refractive-index
detector (Wyatt Technology) and combined inline with a Superdex
200 10/300 size-exclusion column (GE Healthcare) connected to a
Prominence UFLC system (Shimadzu).
2.2. Crystallization and X-ray data collection
The hanging-drop vapour-diffusion technique was used for crys-
tallization. The optimal protein concentration for crystallization was
determined using the PCT screen (Hampton Research). The sparse-
matrix approach was used for initial crystallization screening in 96-
well plates (LabTech) at 293 K. Several commercial screens [Index,
PEG/Ion and PEGRx (Hampton Research), Pact Premier and
JCSG+ (Qiagen), Precipitant Synergy (Emerald BioSystems),
Systematically Controlled Crystallization Screen Set 101 (Axygen
Biosciences) and ProPlex (Molecular Dimensions)] were tested. A
total of 1450 crystallization drops were set up for screening using a
Mosquito robot (TTP LabTech, UK) on hanging-drop seals
(Millennium Science, Australia) by combining 100 nl protein solution
and 100 nl reservoir solution and were equilibrated against 75 ml
reservoir solution. A Rock Imager system (Formulatrix, USA) was
used to monitor the drops.
Crystallization conditions from the initial hits were optimized by
varying the concentration of protein and precipitants, the pH and the
size of the drop in 24-well or 48-well hanging-drop plates (Hampton
Research). For optimization of the crystals, a total of 844 drops were
set up for both the native and SeMet-labelled crystals. The cluster of
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Figure 1
Purification of TRIF-NTD and SeMet-labelled TRIF-NTDA66M/L113M. (a) Gel-
filtration profiles of TRIF-NTD (black) and SeMet-labelled TRIF-NTDA66M/L113M
(orange). The two proteins were run using different chromatographic columns. (b)
SDS–PAGE analysis of purified TRIF-NTD and (c) SeMet-labelled TRIF-
NTDA66M/L113M.
Figure 2
(a) Crystals of TRIF-NTD. (b) Crystals of SeMet-labelled TRIF-NTDA66M/L113M.
The crystals measure 100 mm in the longest dimension.
crystals was broken into individual plates and individual plate-like
crystals were mounted in nylon loops. Prior to flash-cooling in liquid
nitrogen, the crystal was transferred to the mother liquor containing
25% glycerol (tests showed that the cryoprotectant was necessary to
preserve diffraction).
X-ray diffraction data for both TRIF-NTD and TRIF-
NTDA66M/L113M crystals were collected at the Australian Synchrotron
(Table 2). In the case of the crystals of SeMet-labelled TRIF-
NTDA66M/L113M, a fluorescence scan was measured around the
selenium absorption edge to identify the absorption peak and the
wavelength of 0.9793 A˚ was chosen based on this.
MOSFLM (Leslie & Powell, 2007) or XDS (Kabsch, 2010) were
used for indexing and data integration. Data were scaled with
SCALA (Winn et al., 2011) and analysed by POINTLESS (Evans,
2006).
3. Results and discussion
The N-terminal 176 amino acids of TRIF have been previously shown
to form a protease-resistant structural domain (Tatematsu et al.,
2010). Based on this work, we initially produced a protein corre-
sponding to residues 1–177 of TRIFand subjected it to crystallization.
The protein was purified by IMAC and sixe-exclusion chromato-
graphy and estimated by SDS–PAGE to be of greater than 95%
purity. While sparse-matrix screening of this protein yielded some
crystalline material, optimization attempts failed. We therefore
prepared a number of shorter constructs, guided by secondary-
structure predictions. The best-behaved construct corresponded to
residues 1–153 of TRIF (here termed TRIF-NTD). The protein could
be purified by IMAC and size-exclusion chromatography to greater
than 95% purity, with a yield of 10 mg per litre of bacterial culture.
Judging from the gel-filtration profile, the protein was monodisperse,
homogeneous and monomeric (Fig. 1). The molecular mass of the
native protein was also measured by MALLS and was found to
correspond to 15.89  2.38 kDa (the theoretical mass corresponds to
16.99 kDa), consistent with a monomeric protein.
Crystallization screens for native TRIF-NTD yielded clusters of
needle-like microcrystals under 15 different conditions after 2–3 d,
most with conditions containing PEGs of different molecular weights
as precipitant. Based on the morphology of the crystals, we chose
Index screen condition No. 79 (0.1M bis-tris pH 6.5, 200 mM NaCl,
25% PEG 3350) for further optimization. To grow single crystals of
larger size, we varied the pH, the presence of salts and their
concentration, alternative precipitants and their concentration,
different protein:reservoir solution ratios in the drop and drop
volume and different additives. Thin plate-like crystals suitable for
data collection were obtained in 0.1M bis-tris pH 6.6, 150 mM NaCl,
21% PEG 3350 using a protein concentration of 30 mg ml1 (Fig. 2).
Flash-cooled crystals diffracted X-rays to 1.9 A˚ resolution.
TRIF-NTD shares no significant sequence similarity with any
proteins of known structure and therefore structure determination
will require experimental phasing. The crystallized protein contains
two methionines, one of which is the N-terminal residue. We reasoned
that it would be beneficial to introduce additional Met residues. We
analysed a multiple sequence alignment of TRIF homologues and
found two positions, corresponding to Ala66 and Leu113 in human
TRIF, where Met occurred in some of the homologues (Fig. 3). We
used site-directed mutagenesis to generate the TRIF-NTDA66M/L113M
construct. We were able to successfully express and purify SeMet-
labelled TRIF-NTDA66M/L113M (with a yield of 15 mg per litre of
bacterial culture; Fig. 1) and crystallize it under conditions similar to
native TRIF-NTD (0.1M bis-tris pH 6.6, 150 mM NaCl, 28% PEG
3350; protein concentration 20 mg ml1; Fig. 2). The crystals had a
morphology similar to the crystals of the native protein and diffracted
X-rays to 2.5 A˚ resolution.
The crystals of native TRIF-NTD have the symmetry of space
group P212121, while the SeMet-labelled crystals of TRIF-
NTDA66M/L113M have the symmetry of space group P1 (Table 2). The
former and the latter are most likely to contain two and four mole-
cules in the asymmetric unit, respectively (corresponding to a
Matthews coefficient of 2.38 A˚3 Da1, a solvent content of 48.3% and
a probability of 0.68 for TRIF-NTD and a Matthews coefficient of
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Figure 3
Multiple sequence alignment of the N-terminal region of TRIF from different species. Red-coloured columns highlight the positions corresponding to Ala66 and Leu113 in
human TRIF, where methionine substitutions can be found in other species.
2.32 A˚3 Da1, a solvent content of 47% and a probability of 97% for
TRIF-NTDA66M/L113M; analysed using the Matthews Probability
Calculator; Matthews, 1968; Kantardjieff & Rupp, 2003).
The described crystals form a sound foundation to determine the
structure of TRIF-NTD by SAD (single-wavelength anomalous
diffraction) phasing and this work is currently under way. Because the
crystallized domain of TRIF contains no significant sequence simi-
larity to any proteins of known structure, it may reveal a novel
protein fold. The structure will also shed light on the regulation of
TRIF and the interaction of TRIF-NTD with the TIR domain.
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